natgillin/translations-raw huggingface dataset:
Use of a printing sheet according to any of the preceding claims, characterised in that the binder part comprises a binder or a mixture of binders selected from the group consisting of latex, in particular styrene-butadiene, styrene-butadiene-acrylonitrile, styrene-acrylic, in particular styrene-n-butyl acrylic copolymers, styrene-butadiene-acrylic latexes, acrylate vinylacetate copolymers, starch, polyacrylate salt, polyvinyl alcohol, soy, casein, carboxymethyl cellulose, hydroxymethyl cellulose and copolymers as well as mixtures thereof, preferably provided as an anionic colloidal dispersion in the production. 
Upotreba arka za tiskanje prema bilo kojem od prethodnih zahtjeva, naznačena time da vezivni dio sadrži vezivnu tvar ili mješavinu vezivnih tvari odabranih iz skupine koja se sastoji od lateksa, posebice stiren-butadiena, stiren-butadien-akrilonitrila, stiren-akrila, posebice od stiren-n-butil akrilnih kopolimera, stiren-butadien-akrilnih lateksa, akrilat vinilacetatnih kopolimera, škroba, poliakrilatne soli, polivinil alkohola, soje, kazeina, karboksimetil celuloze, hidroksimetil celuloze i kopolimera kao i njihovih mješavina, poželjno po mogućnosti kao anionska koloidna disperzija u proizvodnji.
The process of clause 23, wherein the crude 1,1,1,2,3-pentachloropropane is transformed into 1,1,2,3-tetrachloropropene in step (ii) by reactive distillation, wherein the reactive distillation occurs in equipment comprising a reaction zone, a separation zone, and a condensing zone. The process of clause 23, wherein the 1,1,2,3-tetrachloropropene and hydrogen chloride are removed from the reaction zone via the separation zone and the condensing zone, whereby at least some of the 1,1,2,3-tetrachloropropene is separated as a liquid condensate from the hydrogen chloride vapor, producing purified hydrogen chloride vapor and crude 1,1,2,3-tetrachloropropene. 
Postupak prema zahtjevu 11, gdje se sirovi 1,1,1,2,3-pentakloropropan pretvara u 1,1,2,3-tetrakloropropen reaktivnom destilacijom, gdje se reaktivna destilacija odvija u opremi koja obuhvaća reakcijsku zonu, zonu odvajanja i zonu kondenzacije, gdje se 1,1,2,3-tetrakloropropen i klorovodik uklanjanju iz reakcijske zone putem zone odvajanja i zone kondenzacije, pri čemu se barem dio 1,1,2,3-tetrakloropropena odvaja kao tekući kondenzat iz pare klorovodika, čime nastaje pročišćena klorovodična para 1 sirovi 1,1,2,3-tetrakloropropen.
The pharmaceutical composition of claim 8 which further includes one or more of an antioxidant, colorant, flavor improving agent, preservative, sweetener, binder or lubricant; wherein the carrier comprises carboxymethyl cellulose, crystalline cellulose, glycerin, gum arabic, lactose, magnesium stearate, methyl cellulose, saline, sodium alginate, sucrose, starch, talc or water; with the pharmaceutical composition being in the form of a capsule, tablet, powder, granule, or suspension. 
Farmaceutska kompozicija prema patentnom zahtjevu 2 naznačena time što nosač sadrži karboksimetil celulozu, kristalnu celulozu, glicerin, gumu arabiku, laktozu, magnezijev stearat, metil celulozu, fiziološku otopinu, natrijev alginat, saharozu, škrob, talk ili vodu. Farmaceutska kompozicija prema patentnom zahtjevu 2 naznačena time što je u obliku kapsule, tablete, praška, granule ili suspenzije. Farmaceutska kompozicija prema patentnom zahtjevu 2 naznačena time što dalje sadrži aditiv.
The prosthetic aortic heart valve of one of the preceding claims, wherein the lower ends of two adjacent angled struts (24) of the rows of angled struts are connected by a junction with a U-shape and the upper ends of two adjacent angled struts (22) of the rows of angled struts are connected by a junction with an inverted U-shape. 
Sklop prema jednom od prethodnih patentnih zahtjeva, naznačen time da su donji krajevi dva susjedna kutna nosača (24) redova kutnih nosača povezani spojnicom U oblika i gornji krajevi dva susjedna kutna nosača (22) redova kutnih nosača su povezani spojnicom obrnutog U oblika.
an adjuvant component, comprising or consisting of at least one mRNA, complexed with protamine, and 
Imunostimulacijski pripravak koji sadrži komponentu adjuvanta, koja obuhvaća ili se sastoji od barem jedne
The method according to claim 6 or 7, further comprising: in the uplink synchronous status, not performing uplink timing alignment based on the timing deviation information included in the random access response (S02). 
Postupak obrade prema zahtjevu 5 ili 6, naznačen time da korak odbacivanja nadalje sadrži, u sinkronom statusu uzlazne veze, ne provođenje usklađivanja vremena uzlazne veze na osnovi informacije o odstupanju vremena sadržane u primljenom odgovoru slučajnog pristupa (S02).
Motor 42 would be adjustable to vary the speed of the peristaltic rollers 44, which would be in proportion to the amount of fluid that would be pumped through conduit 14. 
Motor 44 može se podesiti da varira brzinu peristaltičkih valjaka 44, koja će biti proporcionalna količini fluida kojeg je potrebno pumpati kroz cjevovod 14.
Compounds of the Formula VI may be prepared using process (a) or process (e) above, starting with a compound prepared, for example using reaction scheme 1. 
Spojevi prikazani Formulom VI mogu se pripraviti primjenom gore navedenog postupka (a) ili postupka (e), polazeći od spoja pripravljenog, na primjer, prema Reakcijskoj Shemi 1.
The DNA molecule of claim 18, wherein said variable light chain encoding region is fused to a region encoding a constant light chain of human origin, preferably said constant light chain is a kappa chain, preferably said kappa light chain is encoded by a sequence shown in SEQ ID NO:25. 
DNK-molekula prema zahtjevu 14, naznačena time, da se navedeni slabi kappa-lanac kodira pomoću sekvence prikazane u SEQ ID NO:29 ili SEQ ID NO:33 ili SEQ ID NO:25.
nucleic acid sequences depicted in SEQ ID NOs: 49, 54, 59, 69, 69, 74, and 79, or conservative sequence variants thereof; 
sekvence nukleinskih kiselina prikazane u SEQ ID NOs: 49, 54, 59, 69, 69, 74 i 79, ili njihovih konzervativnih varijanta sekvenci;
When the lid 5 is in the hinged open position the container 3 can be placed in the chill space 7 through the opening in the top surface of the chill chamber 2. 
Kad je poklopac 5 pomoću šarke u otvorenom položaju, spremnik 3 se može postaviti u prostor za hlađenje 7 kroz otvor na gornjoj površini komore za hlađenje 2.
at least one of (i) a pressure lowering agent selected from ACE-inhibitors, ARBs and CCBs, and/or (ii) a cholesterol lowering agent selected from statin derivatives, or any pharmaceutically acceptable salt and ester thereof, and 
najmanje jedno od (i) sredstvo za smanjenje tlaka odabrano od ACE-inhibitora, od sredstava ARB i CCB, iili (ii) sredstvo za sniženje kolesterola odabrano od derivata statina, ili njihova bilo koja farmaceutski prihvatljiva sol i njihov takav ester, i
± 59.2 EXAMPLE 3 This example details the pharmacokinetic properties of Fampridine-SR in tablets of the present invention administered to patients with multiple sclerosis. 
Sastav prema bilo kojem od zahtjeva 1 do 4, naznačen time da je postupak tretiranja multiple skleroze povećanje brzine hoda kod pacijenta s multiplom sklerozom.
It is noted that especially in the manufacture of larger products, it may be desirable to be able to steer the resin flows in the different runner channels individually or per group, by providing control or shutoff valves in different (main) runner channels. 
Treba napomenuti da, posebno kod izrade velikih proizvoda, može biti poželjno da se pomoću predviđene kontrole ili zatvaranjem ventila u različitim (glavnim) protočnim kanalima može upravljati smolu tako da ona teče u različite protočne kanale pojedinačno ili po skupinama.
The radio communication terminal apparatus according to claim 1, wherein, the receiver, in operation, receives higher layer control information indicating control of the transmission power value of the A-SRS using the second accumulation value. 
Radio komunikacijski terminalni uređaj sukladno zahtjevu 1, naznačen time da se navedeno upravljanje vrijednosti snage prijenosa A-SRS-a inicira nakon primanja kontrolne informacije višeg sloja.
The formulation of paragraph 1, wherein the dissolution agent is an acid selected from the group consisting of acetic acid, ascorbic acid, citric acid, glutamic, succinic, aspartic, maleic, fumaric, and adipic acid, or a salt thereof. The formulation of paragraph 4 wherein the dissociating agent is citric acid or sodium citrate. The formulation of paragraph 1 wherein the pH is between 7 and 7.5. 
Formulacija prema zahtjevu 1, naznačena time da je sredstvo za otapanje kiselina koja je odabran iz skupine koju čine octena kiselina, askorbinska kiselina, limunska kiselina, glutaminska kiselina, jantarna kiselina, aspartamska kiselina, maleinska kiselina, fumarna kiselina, i adipinska kiselina, ili njihove soli, poželjno limunske kiseline ili natrijevog citrata ili soli koji se biraju iz skupine koju čine acetat, askorbat, citrat, glutamat, aspartat, sukcinat fumarat, maleat, i adipat i skupina I metala skupina II metala, poželjno natrijev ili kalijev askorbat, citrat, glutamat, aspartat, sukcinat, fumarat, maleat, i adipat.
The combination according to claim 1, wherein the phenoxybenzamine is phenoxybenzamine hydrochloride. 
2. < Kombinacija prema zahtjevu 1, naznačena time da fenoksibenzamin je fenoksibenzamin hidroklorid.
preparation of #1 Extract: Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Corydalis and Semen Cassiae are mixed, extracted by using heating refluxing with 3∼6 fold of 50∼80% ethanol for 2∼3 times, the first time for 0.5∼2.5 hours, the second and/or third time for 0.5∼2 hours, and filtered to remove the impurities; and the ethanol is recovered and concentrated until the relative density is 1.250∼1.350 at 70∼80°C to give #1 Extract for later use; 
Priprema ekstrakta br. 1: Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Corydalis i Semen Cassiae se pomiješaju, ekstrahiraju uz refluks i zagrijavanje s 3 do 6 puta većom količinom 50 do 80 % etanola 2 do 3 puta, prvi put u trajanju 0,5 do 2,5 sati, drugi 1 / ili treći put u trajanju od 0,5 do 2 sata 1 filtriraju se kako bi se uklonile nečistoće; i etanol se izdvaja i koncentrira do relativne gustoće 1.250 - 1.350 na 70 do 80"C da se dobije ekstrakt br. 1 za kasniju uporabu; b).
A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: wherein: 
PATENTNI ZAHTJEVI 1. Derivat pirimidona prikazan formulom (1), ili njegova sol, ili njegov solvat ili njegov hidrat:
Process according to one of the claims 1 to 8, wherein the at least one water-soluble acid is dosed in a molar amount relative to the numbers of moles of the calcium carbonate containing mineral in the range from 0.01 mol/mol to about 1 mol/mol, preferably from 0.1 to 0.6 mol/mol. 
Postupak prema jednom od zahtjeva 1 do 7, naznačen time da se barem jedna kiselina koja se otapa u vodi dozira u molarnoj količini u odnosu na broj molova kalcijevog karbonata koji sadrži mineral u rasponu od 0.01 mol/mol do oko 1 mol/mol, poželjno od 0.1 do 0.6 mol/mol.
the cell density is maintained at less than 3.0x106 cells per mL during the step of culturing the one or more cells; or 
gustoću stanica se održava kod manje od 3,0 x 106 stanica po ml u koraku uzgoja jedne ili više stanica; ili
an emergency disconnect power assembly (50) functionally coupled to the engagement mechanism to drive the switching of the engagement mechanism; a switching system (400) arranged between the emergency disconnect power assembly (50) and the engagement mechanism, wherein the switching system is configured to control the switching of the engagement mechanism in the emergency disconnection coupler between the locked position and the unlocked position, wherein the switching system (400) is subject to two distinct fail-safe regimes contingent upon the internal gas pressure in the gas connection: a fail-unlocked regime when the internal gas pressure in the gas connection is below a preselected override threshold value, which sets the switching system to unlock the engagement mechanism upon power loss, and a fail-locked regime which sets the switching system to lock the engagement mechanism when the internal gas pressure in the gas connection is at or above the preselected override threshold value. 
pogonjeni sklop za hitno razdvajanje (50), funkcionalno spregnut s mehanizmom za međudjelovanje, radi pogonjenja prebacivanja mehanizma za međudjelovanje; - prekidački sustav (400), koji se nalazi između pogonjenog sklopa za hitno razdvajanje (50) 1 mehanizma za međudjelovanje, gdje je prekidački sustav konfiguriran za upravljanje prebacivanja mehanizma za međudjelovanje u spojnici za hitno razdvajanje između zabravljenog položaja i odbravljenog položaja, gdje prekidački sustav (400) ima dva različita režima u slučaju kvara ovisno unutarnjem tlaku plina u plinskoj vezi: odbravljeni režim u slučaju kvara kada je unutarnji tlak plina u plinskoj vezi ispod zadane vrijednosti prelaska praga, koji namješta prekidački sustav za odbravljanje mehanizma za međudjelovanje prilikom gubitka napajanja, i zabravljeni režim u slučaju kvara koji namješta prekidački sustav za zabravljivanje mehanizma za međudjelovanje kada je unutarnji tlak plina u plinskoj vezi na ili iznad zadane vrijednosti prelaska praga.
The phases were separated and the aqueous layer was washed with ethyl acetate (3×100 mL). 
Faze se razdvoji, a vodeni sloj ispere etil-acetatom (3 x 100 ml).
in which R and R′ taken together with the nitrogen atom they are linked to are a protected primary amino group, with a compound of formula (XVI): 
(VD u kojem R i R* zajedno s dušikovim atomom za koji su vezani predstavljaju zaštićenu amino-skupinu, sa spojem formule (XVI):
contacting a test compound with a host cell or a membrane of a host cell that expresses a G protein-coupled receptor, wherein said G protein coupled receptor comprises an amino acid sequence selected from the group consisting of: amino acids 1-335 of SEQ ID No: 2; amino acids 2-335 of SEQ ID No:2; 
(a) stavljanje u kontakt test spoja sa stanicom domačina ili membranom stanice domaćina koja izlučuje G protein-kupiran receptor pri čemu navedeni G protein kupirani receptor obuhvaća aminokiselinsku sekvencu izabranu iz skupine koju čine: (i) aminokiseline 1-3355 SEQ ID br. 2; (ii) aminokiseline 2-335 SEQ ID br. 2;
Typical ratios of minimum/maximum particle size within a fraction are e.g. 1:4, preferably 1:3, more preferably 1:2, or even lower, e.g. the particle sizes within a fraction may be 10-30 mm, 30-70 mm, or 60-120 mm. 
Postupak prema zahtjevu 13, naznačen time da je omjer minimalne/maksimalne veličine čestica unutar frakcije 1:4, poželjno 1:3, a još poželjnije 1:2.
Q and R11 and n are as defined in claim 1 and X is a leaving group with compounds of formulae III and IV wherein Z, R1 and R6-R9 are as defined in claim 1; and M is B or a metal. 
definiran u patentnom zahtjevu 1 i X je klor koji je zatim konvertiran u jod prije vezivanja sa spojevima koja su označena formulama III i IV. [image] pri čemu su Z, R1 i R8 definirani kao što je u patentnom zahtjevu 1; i M je B ili metal.
Compounds of general formula wherein 
Spojevi opće formule [image] naznačeni time, da je
A pharmaceutical aerosol solution composition according to claim 4 wherein the stabilising amount of a mineral acid is an amount of acid equivalent to 1M hydrochloric acid in the range from 0.200 to 0.227 µg/µl. 
Farmaceutski pripravak aerosolne otopine prema patentnom zahtjevu 4 u kojem stabilizirajuća količina mineralne kiseline jest količina kiseline ekvivalentna 1M klorovodične kiseline u rasponu od 0,200 do 0,227 ug/ul.
nitrosylation (NOS) before the nitrosyl reduction (NR), in which an N,N- disubstituted-3-optionally substituted aniline, 1, is 4-nitrosylated to give said N,N- disubstituted-3-optionally substituted-4-nitrosyl aniline, 2: 
nitrozilacija (NOS) prije koraka nitrozilne redukcije (NR), u kojoj se N,N-disupstituirani-3-opcionalno supstituirani anilin 1, 4-nitrozilira kako bi dao navedeni N,N-disupstituirani-3-opcionalno supstituirani-4-nitrozil-anilin 2:
Typically the additional active compound (c) is selected from the group consisting of (a) B2 agonists and (b) corticosteroids. 
Obično je dodatni djelatni spoj (c) odabran iz skupine koja se sastoji od (a) inhibitora PDE IV i (b) kortikosteroida.
The immunogenic composition of any one of embodiments 49-60 wherein the same carrier protein is used in the Hib conjugate and two or more of the at least two further bacterial saccharide conjugates. 
Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što isti proteinski nosač se upotrebljava u konjugatu Hib i u dva ili više od najmanje dva dodatna konjugata bakterijskih saharida.
The isolated nucleic acid molecule of claim 5 or 6, wherein said nucleic acid molecule encodes said immunogenic polypeptide as a fusion protein comprising a secretory signal sequence. 
Izolirana molekula nuklemske kiseline prema zahtjevu 5 ili 6, naznačena time, da molekula nuklemske kiseline kodira navedeni ununogeni polipeptid kao fuzijski protein koji sadrži sekrecijski signalni slijed.
A method according to claim 6, wherein the disease or condition is asthma or chronic obstructive pulmonary disease (COPD). A method according to claim 6, wherein said subject is a human. 
Pripravak za primjenu prema zahtjevu 8 ili 9, naznačen time, što je bolest 1li stanje astma ili kronična opstruktivna plućna bolest (COPD).
to 1 wt.-%, particularly 0.01 to 0.8 wt.-%, more preferably 0.1 to 0.7 wt.-% of coloring agent. 
bojilo od 0 do 1 masenih %, posebno od 0,01 do 0,8 masenih %, najbolje od 0,1 do 0,7 masenih %.
The method according to claim 8, characterised in that the adjusted medication dose AD is equal to the first dose if the variable B is negative and is equal to the second dose if the variable B is positive. 
Metoda u skladu sa zahtjevom 8 naznačena time da je prilagođena doza lijekova AD jednaka prvoj dozi ukoliko je varijabla B negativna a jednaka drugoj dozi ako je varijabla B pozitivna.
The compound of any one of claims 6-7, wherein Z is selected from-pyrazinyl, pyridinyl, pyridazinyl and piperazinyl; wherein each pyrazinyl, pyridinyl, pyridazinyl or piperazinyl of Z is optionally substituted with an R6 group. 
Spoj prema bilo kojem od zahtjeva 6 do 7, naznačen time, da je Z odabran od sljedećih: pirazinil, piridinil, piridazinil i piperazinil; pri čemu je svaki pirazinil, piridinil, piridazinil ili piperazinil od Z opcijski supstituiran s R6-skupinom.
The jack system of claim 1, wherein the seating means comprises a peripheral edge of a semi-circular cut-out portion formed in a central region of each of the respective arms. 
Sustav dizalica (10, 100) sukladno zahtjevu 2, naznačen time da sredstvo sjedišta (26, 126) sadrži periferni rub polukružnog izrezanog dijela oblikovanog u središnjem području svakog odnosnog kraka (20,120).
The device according to claim 1, characterized in that the means for manipulating at the lateral edges of the nail have a form of deflecting spatulas configured to deflect aside flesh of lateral nail folds. 
Naprava prema zahtjevu 1, naznačena time što sredstva (131, 132; 231, 232) za manipulaciju kod bočnih ivica nokta imaju oblik svijajućih lopatica (411, 412) prilagođenih za savijanje u stranu mesa bočnih kožnih nabora oko nokta.
determining whether the compound stimulates GLP-1 secretion from the mammalian enteroendocrine cell; wherein the ability of the test compound to stimulate GLP-1 secretion from the mammalian enteroendocrine cell is indicative of the test compound being a GLP-1 secretagogue or a compound useful for treating or preventing a condition ameliorated by increasing a blood GLP-1 level. 
(d) određivanja da li spoj stimulira GLP-1 sekreciju iz enteroendokrine stanice sisavca; pri čemu je sposobnost test spoja da stimulira GLP-! sekreciju iz enteroendokrine stanice sisavca nadalje indikativna da je test spoj GLP-1 sekretogog.
Thus, the technique of using the photosensitivity range proved to be a good model to study the epileptic properties of a single dose of an experimental drug in humans. 
Stoga, se tehnika koja koristi raspon fotosenzitivnosti pokazala kao dobar model za proučavanje epileptičkih svojstava pojedinačne doze eksperimentalnog lijeka kod ljudi.
On the contrary, there was no change of roughness on the untreated nails, whose Ra score were 9.78±3.37 at baseline, 9.82±3.31 after 14 days and 10.32±3.4 at the end of the observation period. 
Nasuprot tome, nije bilo promjena u naboranosti na netretiranim noktima, čija je vrijednost Ra bila 9,78 + 3,37 na početku tretmana, 9,82 + 3,31 nakon 14 dana i 10,32 + 3,4 na kraju perioda praćenja.
The process according to previous Claims, characterised by the fact that pulsed DC voltage is applied up to 10 KV and at a frequency of up to 250 KHz for the generation of plasma from atmospheric air at a pressure from 8x10-2 to 1x100 mbar in order to begin and conclude the sterilization under vacuum and elimination of the residues. 
Postupak u skladu s prethodnim patentnim zahtjevima, naznačen time, da se za generiranje plazme iz atmosferskog zraka koristi puls istosmjerne struje napona do 10 KV i frekvencije do 250 KHz, pri tlaku u rasponu od 8x10* do 1x10* mbar za početak i završetak sterilizacije pod vakuumom i uklanjanje ostataka.
detecting the presence of a mutation in RET in a sample obtained from the patient; and determining or preliminarily determining that the patient has sensitivity to the compound, the salt thereof or the solvate thereof, on the basis of the presence of a mutation in RET in the sample: wherein R1 is a C1-6 alkyl group. 
detektiranja prisutnosti mutacije u RET-u u uzorku dobivenom iz pacijenta; i određivanje ili preliminarno određivanje da je pacijent osjetljiv na spoj, njegovu sol ili njegov solvat, na osnovi prisutnosti mutacije u RET-u u uzorku:
7a. In another embodiment the invention is a compound of any of statements 1a to 4a for use in the treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, optionally including malignant neoplasias and metastasis. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što je namijenjen upotrebi u liječenju prekanceroznih lezija, displazija, metaplazija i tumorskih bolesti, što može uključivati zloćudne novotvorine i metastaze.
The filtrate is evaporated to dryness, the residue is stirred for one hour with a mixture of TBME and heptane 7/3 v/v, filtered and dried in vacuum. 
Filtrat se evaporira do suhoga, ostatak se miješa tijekom jedng sata sa smjesom TBME i heptana 7/3 v/y, filtrira se i suši u vakuumu.
The same also applies to the thickness/gage of the pieces of materials being different from wood that are incorporated into the wood composite. 
Isto se dakle primjenjuje na debljinu/kalibar komada materijala koji su različiti od drva i koji su ugrađeni u kompoziciju od drva.
and R2 are an alkali metal, wherein the alkali metal is preferably selected from the group consisting of lithium, sodium and potassium, 
(iv) R,iR> su alkalijski metal, pri čemu je alkalijski metal poželjno odabran iz skupine koju čine litij, natrij 1 kalij,
In a fifth aspect of the invention, there is provided the use of a compound according to the invention in its first or second aspects for the manufacture of a medicament for use in the treatment of cancer. 
U petom aspektu izuma, donosi se upotreba spoja prema izumu u njegovom prvom ili drugom aspektu za proizvodnju lijeka za upotrebu u tretiranju raka.
a water inlet fitting configured to connect said “float valve” connected device on a pipe of the sanitary facility; 
• spojnicu za dovod vode (7A-2) koja omogućava spajanje navedenog plutajućeg ventila na cijev sanitarnog čvora;
The aqueous pharmaceutical suspension according to claim 76, further comprising, by weight/volume (g/100 mL), 0.1% of titanium dioxide. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 86, naznačena time što izborno dodatno sadrži, težinski/volumno (g/100 ml), otprilike 0,1 % titanijevog dioksida.